Biomarkers for risk stratification of neoplastic progression in Barrett esophagus

Cellular Oncology

Volumn 29, Issue 6, 2007, Pages 507-517

  Kerkhof, Marjon ^a   Kusters, Johannes G ^a   Van Dekken, Herman ^a   Kuipers, Ernst J ^a   Siersema, Peter D ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Barrett esophagus; Biomarkers; Esophageal adenocarcinoma

Indexed keywords

BETA CATENIN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLOOXYGENASE 2; DNA; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN;

BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER RISK; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; PLOIDY; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BARRETT ESOPHAGUS; CELL ADHESION MOLECULES; CELL CYCLE PROTEINS; DISEASE PROGRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM STAGING; PLOIDIES; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 36248987758     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. B. Avidan, A. Sonnenberg, T.G. Schnell, G. Chejfec, A. Metz and S.J. Sontag, Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma, Am. J. Gastroenterol. 97 (2002), 1930-1936.
2. J.P. Baak, F.J. ten Kate, G.J. Offerhaus, J.J. van Lanschot and G.A. Meijer, Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies, J. Clin. Pathol. 55 (2002), 910-916.
3. T. Bailey, L. Biddlestone, N. Shepherd, H. Barr, P. Warner and J. Jankowski, Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation, Am. J. Pathol. 152 (1998), 135-144.
4. K. Bani-Hani, I.G. Martin, L.J. Hardie, N. Mapstone, J.A. Briggs, D. Forman and C.P. Wild, Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma, J. Natl. Cancer Inst. 92 (2000), 1316-1321.
5. M.T. Barrett, C.A. Sanchez, P.C. Galipeau, K. Neshat, M. Emond and B.J. Reid, Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus, Oncogene 13 (1996), 1867-1873.
6. D.A. Bax, P.D. Siersema, A.H. Van Vliet, E.J. Kuipers and J.G. Kusters, Molecular alterations during development of esophageal adenocarcinoma, J. Surg. Oncol. 92 (2005), 89-98 (discussion 99).
7. J. Behrens, Cadherins and catenins: role in signal transduction and tumor progression, Cancer Metastasis Rev. 18 (1999), 15-30.
8. M. Beilstein and D. Silberg, Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma, Gastroenterol. Clin. N. Am. 31 (2002), 461-479.
9. Y.S. Bian, M.C. Osterheld, F.T. Bosman, C. Fontolliet and J. Benhattar, Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus, Am. J. Clin. Pathol. 114 (2000), 583-590.
10. P.L. Blount, P.C. Galipeau, C.A. Sanchez, K. Neshat, D.S. Levine, J. Yin, H. Suzuki, J.M. Abraham, S.J. Meltzer and B.J. Reid, 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy, Cancer Res. 54 (1994), 2292-2295.
11. P.L. Blount, S. Ramel, W.H. Raskind, R.C. Haggitt, C.A. Sanchez, P.J. Dean, P.S. Rabinovitch and B.J. Reid, 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma, Cancer Res. 51 (1991), 5482-5486.
12. N.S. Buttar and K.K. Wang, Mechanisms of disease: Carcinogenesis in Barrett's esophagus, Nat. Clin. Pract. Gastroenterol. Hepatol. 1 (2004), 106-112.
13. A.G. Casson, Z. Zheng, S.C. Evans, L. Geldenhuys, S.V. van Zanten, P.J. Veugelers, G.A. Porter and D.L. Guernsey, Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma, Cancer 104 (2005), 730-739.
14. G. Cattoretti, M.H. Becker, G. Key, M. Duchrow, C. Schluter, J. Galle and J. Gerdes, Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections, J. Pathol. 168 (1992), 357-363.
15. E. Cheong, L. Igali, I. Harvey, M. Mole, E. Lund, I.T. Johnson and M. Rhodes, Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study, Aliment. Pharm. Ther. 17 (2003), 379-386.
16. M. Conio, S. Blanchi, G. Lapertosa, R. Ferraris, R. Sablich, S. Marchi, V. D'Onofrio, T. Lacchin, G. Iaquinto, G. Missale, P. Ravelli, R. Cestari, G. Benedetti, G. Macri, R. Fiocca, F. Munizzi and R. Filiberti, Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study, Am. J. Gastroenterol. 98 (2003), 1931-1939.
17. D.A. Corley, T.R. Levin, L.A. Habel, N.S. Weiss and P.A. Buffler, Surveillance and survival in Barrett's adenocarcinomas: a population-based study, Gastroenterology 122 (2002), 633-640.
18. P. Duesberg, R. Li, A. Fabarius and R. Hehlmann, The chromosomal basis of cancer, Cell. Oncol. 27 (2005), 293-318.
19. G.S. Dulai, S. Guha, K.L. Kahn, J. Gornbein and W.M. Weinstein, Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review, Gastroenterology 122 (2002), 26-33.
20. G.W. Falk, Barrett's esophagus-is it bad for your health?, Am. J. Gastroenterol. 100 (2005), 2622-2623.
21. M.B. Fennerty, R.E. Sampliner, D. Way, R. Riddell, K. Steinbronn and H.S. Garewal, Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus, Gastroenterology 97 (1989), 815-820.
22. J.F. Flejou and M. Svrcek, Barrett's oesophagus - a pathologist's view, Histopathology 50 (2007), 3-14.
23. M. Gaasenbeek, K. Howarth, A.J. Rowan, P.A. Gorman, A. Jones, T. Chaplin, Y. Liu, D. Bicknell, E.J. Davison, H. Fiegler, N.P. Carter, R.R. Roylance and I.P. Tomlinson, Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers, Cancer Res. 66 (2006), 3471-3479.
24. P.C. Galipeau, X. Li, P.L. Blount, C.C. Maley, C.A. Sanchez, R.D. Odze, K. Ayub, P.S. Rabinovitch, T.L. Vaughan and B.J. Reid, NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma, PLoS Med. 4 (2007), 342-354 (e67).
25. P.C. Galipeau, L.J. Prevo, C.A. Sanchez, G.M. Longton and B.J. Reid, Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue, J. Natl. Cancer Inst. 91 (1999), 2087-2095.
26. H. Geddert, S. Kiel, R.B. Zotz, J. Zhang, R. Willers, H.E. Gabbert and M. Sarbia, Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract, J. Cancer Res. Clin. Oncol. 131 (2005), 803-808.
27. P. Gillen, M. McDermott, D. Grehan, D.O. Hourihane and T.P. Hennessy, Proliferating cell nuclear antigen in the assessment of Barrett's mucosa, Br. J. Surg. 81 (1994), 1766-1768.
28. A. Gimenez, A. Minguela, L.M. de Haro, P. Parrilla, J. Bermejo, D. Perez, A.M. Garcia, M.A. Ortiz, J. Molina and R. Alvarez, DNA ploidy status and proliferative activity as markers of malignant potential in Barrett's esophagus: flow cytometric study using routinely paraffin-embedded tissue, World J. Surg. 24 (2000), 72-77.
29. A. Gimenez, A. Minguela, P. Parrilla, J. Bermejo, D. Perez, J. Molina, A.M. Garcia, M.A. Ortiz, R. Alvarez and L.M. de Haro, Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus, Cancer 83 (1998), 641-651.
30. M.V. Gonzalez, M.L. Artimez, L. Rodrigo, C. Lopez-Larrea, M.J. Menendez, V. Alvarez, R. Perez, M.F. Fresno, M.J. Perez, A. Sampedro and E. Coto, Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma, J. Clin. Pathol. 50 (1997), 212-217.
31. M. Hage, P.D. Siersema, H. van Dekken, E.W. Steyerberg, J. Dees and E.J. Kuipers, Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years, Scand. J. Gastroenterol. 39 (2004), 1175-1179.
32. R.C. Haggitt, Barrett's esophagus, dysplasia, and adenocarcinoma, Hum. Pathol. 25 (1994), 982-993.
33. W. Hameeteman, G.N. Tytgat, H.J. Houthoff and J.G. van den Tweel, Barrett's esophagus: development of dysplasia and adenocarcinoma, Gastroenterology 96 (1989), 1249-1256.
34. R. Hamelin, J.F. Flejou, F. Muzeau, F. Potet, P. Laurent-Puig, F. Fekete and G. Thomas, TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus, Gastroenterology 107 (1994), 1012-1018.
35. S.R. Hamilton and R.R. Smith, The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus, Am. J. Clin. Pathol. 87 (1987), 301-312.
36. L.J. Hardie, S.J. Darnton, Y.L. Wallis, A. Chauhan, P. Hainaut, C.P. Wild and A.G. Casson, p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations, Cancer Lett. 217 (2005), 221-230.
37. S. Haupt, M. Berger, Z. Goldberg and Y. Haupt, Apoptosis - the p53 network, J. Cell Sci. 116 (2003), 4077-4085.
38. D.W. Hedley, Flow cytometry using paraffin-embedded tissue: five years on, Cytometry 10 (1989), 229-241.
39. P.W. Hinds, C.A. Finlay, R.S. Quartin, S.J. Baker, E.R. Fearon, B. Vogelstein and A.J. Levine, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes, Cell Growth Differ. 1 (1990), 571-580.
40. M.K. Hong, W.B. Laskin, B.E. Herman, M.H. Johnston, J.J. Vargo, S.M. Steinberg, C.J. Allegra and P.G. Johnston, Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus, Cancer 75 (1995), 423-429.
41. A.P. Ireland, G.W. Clark and T.R. DeMeester, Barrett's esophagus. The significance of p53 in clinical practice, Ann. Surg. 225 (1997), 17-30.
42. J. Jankowski, R. McMenemin, C. Yu, D. Hopwood and K.G. Wormsley, Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression, Gut 33 (1992), 587-591.
43. K. Jaskiewicz, J. Louw and N. Anichkov, Barrett's oesophagus: mucin composition, neuroendocrine cells, p53 protein, cellular proliferation and differentiation, Anticancer Res. 14 (1994), 1907-1912.
44. R.N. Keswani, A. Noffsinger, I. Waxman and M. Bissonnette, Clinical use of p53 in Barrett's esophagus, Cancer Epidem. Biomarkers Prev. 15 (2006), 1243-1249.
45. M.C. Kimos, S. Wang, A. Borkowski, G.Y. Yang, C.S. Yang, K. Perry, A. Olaru, E. Deacu, A. Sterian, J. Cottrell, J. Papadimitriou, L. Sisodia, F.M. Selaru, Y. Mori, Y. Xu, J. Yin, J.M. Abraham and S.J. Meltzer, Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression, Int. J. Cancer 111 (2004), 415-417.
46. K.K. Krishnadath, H.W. Tilanus, M. van Blankenstein, F.T. Bosman and A.H. Mulder, Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus, J. Pathol. 175 (1995), 175-180.
47. K.K. Krishnadath, H.W. Tilanus, M. van Blankenstein, W.C. Hop, R. Teijgeman, A.H. Mulder, F.T. Bosman and H. van Dekken, Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus, Cancer Res. 55 (1995), 1971-1976.
48. H. Kuramochi, D. Vallbohmer, K. Uchida, S. Schneider, N. Hamoui, D. Shimizu, P.T. Chandrasoma, T.R. DeMeester, K.D. Danenberg, P.V. Danenberg and J.H. Peters, Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma, J. Gastrointest. Surg. 8 (2004), 1007-1017.
49. C. Lagorce, F. Paraf, D. Vidaud, A. Couvelard, D. Wendum, A. Martin and J.F. Flejou, Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma, Histopathology 42 (2003), 457-465.
50. L.A. Lai, T.G. Paulson, X. Li, C.A. Sanchez, C. Maley, R.D. Odze, B.J. Reid and P.S. Rabinovitch, Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH, Genes Chromosomes Cancer 46 (2007), 532-542.
51. P. Lao-Sirieix, R. Brais, L. Lovat, N. Coleman and R.C. Fitzgerald, Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis, Neoplasia 6 (2004), 751-760.
52. A.J. Levine, J. Momand and C.A. Finlay, The p53 tumour suppressor gene, Nature 351 (1991), 453-456.
53. C.C. Maley, P.C. Galipeau, X. Li, C.A. Sanchez, T.G. Paulson, P.L. Blount and B.J. Reid, The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma, Cancer Res. 64 (2004), 7629-7633.
54. D.T. McManus, A. Olaru and S.J. Meltzer, Biomarkers of esophageal adenocarcinoma and Barrett's esophagus, Cancer Res. 64 (2004), 1561-1569.
55. S. Mehta, A. Boddy, I.T. Johnson and M. Rhodes, Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis, Aliment. Pharmacol. Ther. 24 (2006), 1321-1331.
56. E. Merola, P.P. Claudio and A. Giordano, p53 and the malignant progression of Barrett's esophagus, J. Cell. Physiol. 206 (2006), 574-577.
57. E. Montgomery, M.P. Bronner, J.R. Goldblum, J.K. Greenson, M.M. Haber, J. Hart, L.W. Lamps, G.Y. Lauwers, A.J. Lazenby, D.N. Lewin, M.E. Robert, A.Y. Toledano, Y. Shyr and K. Washington, Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation, Hum. Pathol. 32 (2001), 368-378.
58. E. Montgomery, J.R. Goldblum, J.K. Greenson, M.M. Haber, L.W. Lamps, G.Y. Lauwers, A.J. Lazenby, D.N. Lewin, M.E. Robert, K. Washington, M.L. Zahurak and J. Hart, Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study, Hum. Pathol. 32 (2001), 379-388.
59. E.A. Montgomery, D.P. Hartmann, N.J. Carr, D.A. Holterman, L.H. Sobin and N. Azumi, Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies, Am. J. Clin. Pathol. 106 (1996), 298-304.
60. C.D. Morris, G.R. Armstrong, G. Bigley, H. Green and S.E. Attwood, Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence, Am. J. Gastroenterol. 96 (2001), 990-996.
61. L. Murray, A. Sedo, M. Scott, D. McManus, J.M. Sloan, L.J. Hardie, D. Forman and C.P. Wild, TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort, Gut 55 (2006), 1390-1397.
62. M.J. Naya, D. Pereboom, J. Ortego, J.O. Alda and A. Lanas, Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits, Gut 40 (1997), 175-181.
63. P.C. Nowell, The clonal evolution of tumor cell populations, Science 194 (1976), 23-28.
64. M. Ohbu, N. Kobayashi and I. Okayasu, Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis: stepwise over-expression of cyclin E and p53, reduction of p21(WAF1/CIP1) and dysregulation of cyclin D1 and p27(KIP1), Histopathology 39 (2001), 589-596.
65. M. Olvera, K. Wickramasinghe, R. Brynes, X. Bu, Y. Ma and P. Chandrasoma, Ki67 expression in different epithelial types in columnar lined oesophagus indicates varying levels of expanded and aberrant proliferative patterns, Histopathology 47 (2005), 132-140.
66. W. Polkowski, J.P. Baak, J.J. van Lanschot, G.A. Meijer, L.T. Schuurmans, F.J. Ten Kate, H. Obertop and G.J. Offerhaus, Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation, J. Pathol. 184 (1998), 161-168.
67. P.S. Rabinovitch, G. Longton, P.L. Blount, D.S. Levine and B.J. Reid, Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables, Am. J. Gastroenterol. 96 (2001), 3071-3083.
68. P.S. Rabinovitch, B.J. Reid, R.C. Haggitt, T.H. Norwood and C.E. Rubin, Progression to cancer in Barrett's esophagus is associated with genomic instability, Lab. Invest. 60 (1989), 65-71.
69. S. Ramel, B.J. Reid, C.A. Sanchez, P.L. Blount, D.S. Levine, K. Neshat, R.C. Haggitt, P.J. Dean, K. Thor and P.S. Rabinovitch, Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry, Gastroenterology 102 (1992), 1220-1228.
70. B.J. Reid, P.L. Blount, C.E. Rubin, D.S. Levine, R.C. Haggitt and P.S. Rabinovitch, Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort, Gastroenterology 102 (1992), 1212-1219.
71. B.J. Reid, R.C. Haggitt, C.E. Rubin and P.S. Rabinovitch, Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma, Gastroenterology 93 (1987), 1-11.
72. B.J. Reid, R.C. Haggitt, C.E. Rubin, G. Roth, C.M. Surawicz, G. Van Belle, K. Lewin, W.M. Weinstein, D.A. Antonioli, H. Goldman et al., Observer variation in the diagnosis of dysplasia in Barrett's esophagus, Hum. Pathol. 19 (1988), 166-178.
73. B.J. Reid, D.S. Levine, G. Longton, P.L. Blount and P.S. Rabinovitch, Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets, Am. J. Gastroenterol. 95 (2000), 1669-1676.
74. B.J. Reid, L.J. Prevo, P.C. Galipeau, C.A. Sanchez, G. Longton, D.S. Levine, P.L. Blount and P.S. Rabinovitch, Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression, Am. J. Gastroenterol. 96 (2001), 2839-2848.
75. B.J. Reid, C.A. Sanchez, P.L. Blount and D.S. Levine, Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression, Gastroenterology 105 (1993), 119-129.
76. M.J. Renan, How many mutations are required for tumorigenesis? Implications from human cancer data, Mol. Carcinog. 7 (1993), 139-146.
77. R.E. Sampliner, Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus, Am. J. Gastroenterol. 97 (2002), 1888-1895.
78. R.J. Schlemper, Y. Kato and M. Stolte, Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists, J. Gastroenterol. 36 (2001), 445-456.
79. R.J. Schlemper, R.H. Riddell, Y. Kato, F. Borchard, H.S. Cooper, S.M. Dawsey, M.F. Dixon, C.M. Fenoglio-Preiser, J.F. Flejou, K. Geboes, T. Hattori, T. Hirota, M. Itabashi, M. Iwafuchi, A. Iwashita, Y.I. Kim, T. Kirchner, M. Klimpfinger, M. Koike, G.Y. Lauwers, K.J. Lewin, G. Oberhuber, F. Offner, A.B. Price, C.A. Rubio, M. Shimizu, T. Shimoda, P. Sipponen, E. Solcia, M. Stolte, H. Watanabe and H. Yamabe, The Vienna classification of gastrointestinal epithelial neoplasia, Gut 47 (2000), 251-255.
80. T. Scholzen and J. Gerdes, The Ki-67 protein: from the known and the unknown, J. Cell. Physiol. 182 (2000), 311-322.
81. J.P. Seery, K.N. Syrigos, A.J. Karayiannakis, A. Valizadeh and M. Pignatelli, Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus, Acta Oncol. 38 (1999), 945-948.
82. D. Shimizu, D. Vallbohmer, H. Kuramochi, K. Uchida, S. Schneider, P.T. Chandrasoma, H. Shimada, T.R. DeMeester, K.D. Danenberg, J.H. Peters, S.R. DeMeester and P.V. Danenberg, Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2, Int. J. Cancer 119 (2006), 765-770.
83. V.N. Shirvani, R. Ouatu-Lascar, B.S. Kaur, M.B. Omary and G. Triadafilopoulos, Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure, Gastroenterology 118 (2000), 487-496.
84. S. Swami, S. Kumble and G. Triadafilopoulos, E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study, Am. J. Gastroenterol. 90 (1995), 1808-1813.
85. P.J. Symmans, J.M. Linehan, M.J. Brito and M.I. Filipe, p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7, J. Pathol. 173 (1994), 221-226.
86. L. Teodori, W. Gohde, M. Persiani, F. Ferrario, D. Tirindelli Danesi, C. Scarpignato, U. Di Tondo, P. Alo and L. Capurso, DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients, Cytometry 34 (1998), 257-263.
87. K. Washington, A. Chiappori, K. Hamilton, Y. Shyr, C. Blanke, D. Johnson, J. Sawyers and D. Beauchamp, Expression of betacatenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas, Mod. Pathol. 11 (1998), 805-813.
88. D.J. Wong, M.T. Barrett, R. Stoger, M.J. Emond and B.J. Reid, p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas, Cancer Res. 57 (1997), 2619-2622.
89. D.J. Wong, T.G. Paulson, L.J. Prevo, P.C. Galipeau, G. Longton, P.L. Blount and B.J. Reid, p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium, Cancer Res. 61 (2001), 8284-8289.
90. M. Younes, R.M. Lebovitz, L.V. Lechago and J. Lechago, p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study, Gastroenterology 105 (1993), 1637-1642.